Skip to main content

Patrick L. Shannon, M.D.

Specialist

  • Medicare participating

At a glance

Years since graduation
31
In the NPI registry since
2005
Medicare patients seen, 2024
1,003

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1995Medical school: Northeastern Ohio University College of Medicine
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Specialist primary
    OH license 35076264S

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
1,003
Services billed
5,648
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Destruction of precancer skin growth, 2-14 growths1,473279
Established patient office or other outpatient visit, 20-29 minutes780589
Destruction of precancer skin growth, 1 growth481369
Pathology examination of tissue using a microscope, intermediate complexity346222
Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks276213
Destruction of skin growth, 1-14 growths212186
Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm115105
Established patient office or other outpatient visit, 30-39 minutes10192
Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks8670
Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm8572

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 24 companies reported 74 payments worth $2,437 in total to this clinician.

By type
Food and Beverage$2,394
Education$42.99

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Apr 29, 2025Janssen Biotech, Inc.
Apr 29, 2025
Education
TREMFYA · Immunology · in-kind
$42.99

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Ohio →

Industry-funded research

Named as a principal investigator on 16 industry-funded studies in 2025, from 8 companies. The companies reported $1,160,524 in research payments for these studies, mostly to the institutions running them.

  • Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
    Eli Lilly and Company · Completed · NCT06588283
  • A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis
    Sun Pharmaceutical Industries Inc.
  • A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients wi…
    Novartis Pharmaceuticals Corporation
  • A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic hand and foot d…
    Eli Lilly and Company
  • A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
    Incyte Corporation
  • A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Contro…
    Amgen Inc.
  • Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
    Sanofi US Services Inc. · Recruiting · NCT05263206
  • A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopi…
    Janssen Research & Development, LLC
  • A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderat…
    Janssen Research & Development, LLC
  • A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affec…
    Janssen Research & Development, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Specialist clinicians in Boardman

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 8, 2007), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1316933260. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.